Professor, Department of Pharmacy,
BITS Pilani, Pilani Campus
S.No | Name | Project title | Year started | Funding |
1 | Dr. Vigneshwaran Pitchaimani | Alternate day fasting resembles recurrent insulin-induced hypoglycemia model in rat | April 2018 to March 2020 | SERB-NPDF |
2 | Dr. Vivek Akhouri | Interdisciplinary life science programme for advanced research and education in epigenetics and genome editing | 29 August 2022 | DBT-BUILDER |
S.No | Name | Thesis title | Completion year | Present status |
1 |
Dr. Almesh Kadakol
(Supervisor)
|
Role of angiotensin II on vascular epigenetics in the development of atherosclerosis and therapeutic intervention of esculetin under type 2 diabetic conditions associated with renal failure | 23rd April 2018 | Therapy Lead, MedTech & Lead MSL, Oncology, Alkem Laboratories Ltd., Mumbai |
2 |
Dr. Santosh Kumar Goru
(Supervisor)
|
Role of histone ubiquitination and ACE2 activation in the progression of renal fibrosis in type I diabetic kidney | 9th Jan 2018 | Community Pharmacist New Brunswick, Loblaw companies Limited, Canada |
3 |
Dr. Anuradha Pandey
(Supervisor) |
Role of epigenetics in modulating inflammatory response mediated by NF-kB through AT1 or AT2 receptor in the development of renal failure under type II diabetic condition | 21st March 2018 | Senior medical writer, Indegene Ltd, Bengaluru |
4 |
Dr. Vajir Malek
(Supervisor) |
Role of neprilysin in the development of cardiovascular and renal complications associated with type 1 diabetes | 5th Feb 2020 | Postdoctoral fellow, Beckman Research Institute, City of Hope, California, United States |
5 |
Dr. Nisha Sharma
(Supervisor) |
Involvement of histone H3 methylation, angiotensin converting enzyme 2, and angiotensin II type 2 receptor in the pathogenesis of acute kidney injury under type 1 diabetic and non-diabetic conditions | 22nd Oct 2020 | Postdoctoral fellow, Arthur Riggs Diabetes Metabolism Research Institute, City of Hope, California, United States |
6 |
Dr. Himanshu Sankrityayan (Supervisor)
|
Understanding the role and regulation of endoplasmic stress in the development of endothelial dysfunction and kidney disease under type 1 diabetic condition | 27th Sept 2022 | Medical Science Liaison (Ophthalmology), North India, Bayer Zydus Pharmaceuticals Pvt. Ltd., Delhi |
7 |
Dr. Ajinath Kale
(Supervisor) |
Klotho regulation as a novel therapeutic strategy against acute kidney injury-diabetes comorbidity | 4th Aug 2023 | Senior research associate, Pharmacology department, Zydus research centre, Ahemadabad, Gujarat |
8 |
Dr. Vishwadeep Shelke
(Supervisor) |
Inflammation targeted pharmacotherapy for diabetic acute kidney injury: Exploring novel combinations | 6th June 2024 | Postdoctoral fellow, Department of Physiology, School of Medicine, Tulane University, New Orleans, LA, United States |
9 | Dr. Prabhjeet Singh
(Co-supervisor)
|
Actively targeted nano-carrier system for the co-delivery of temozolomide and an autophagy modulator for the treatment of glioblastoma multiforme | 13th Sept 2024 | --- |
S.No | Name | Thesis title | Year started | Status |
1 | Ms. Ankita Sharma (Co-supervisor) |
Understanding hyperglycemia-induced epigenetic alterations contributing to drug resistance and progression of human pancreatic cancer | Dec 2020 | Thesis submitted |
2 |
Ms. Neha Dagar
(Supervisor) |
Evaluating the role and putative mechanisms of selected nutraceuticals against acute kidney injury under diabetic condition based on network pharmacology approach and experimental validation | Sept 2021 | Work in progress |
3 |
Ms. Shikha Thakur
(Co-Supervisor) |
Design, synthesis, and biological evaluation of Angiotensin II type 1 receptor (AT1R) – neprilysin (NEP) inhibitors (ARNi) against diabetic cardiomyopathy (DCM) | Sept 2021 | Work in progress |
4 |
Mr. Srinjoy Chakraborty
(Co-Supervisor)
|
Investigating the epigenetic landscape of histone H4 modifications in endothelial dysfunction during diabetes | Sept 2022 | Work in progress |
5 |
Mr. Gurmeet Singh
(Co-Supervisor) |
Identification, isolation, characterization of process and degradation impurities of active pharmaceutical ingredients | Jan 2023 | Work in progress |
6 |
Mr. Bhupendra Puri
(Supervisor)
|
Role of long non-coding RNAs in acute kidney injury-to-chronic kidney disease (AKI-to-CKD) transition | July 2023 | Work in progress |
7 |
Mr. Rohan Bhadange
(Supervisor)
|
Novel pharmacological interventions against chronic kidney disease using clinically approved inodilators, ET-1A antagonists, and bisphosphonates: drug repurposing approach |
Jan 2024 |
Work in progress |
8 |
Mr. Yugant Talati
(Supervisor)
|
A network pharmacology-based evaluation and experimental validation of phytopharmaceuticals as promising pharmacological interventions for chronic kidney disease | Jan 2024 | Work in progress |
9 |
Ms. Mansi Trivedi
(Supervisor)
|
Study of novel pharmacological combinations against diabetic cardiomyopathy | Jan 2024 | Work in progress |
10 |
Mr. Aditya Dipakrao Hajare
(Supervisor)
|
Pharmacological intervention using α-Klotho with AT1 receptor blocker and sodium-glucose co-transporter 2 (SGLT-2) inhibitor against diabetic kidney disease | May 2024 | Work in progress |
S.No | Name | Thesis title | Year |
1 | Mr. Jaspreet Singh | To evaluate the hepatoprotective and hepatocurative activity of Punica Granatum peels | 2013 |
2 | Mr. Virendra Singh | Life saving potential of NMD 04 intravenous fluid against animal models of hemorrhagic shock | 2013 |
3 | Mr. Vishakh Prabhkar | Biological clock and parkinsonism: Influence of the neurohormone, melatonin on experimental model of parkinson’s disease (Co-supervisor) | 2014 |
4 | Mr. Shreyash Bagal | To study the expression of angiotensin – II (AT1 & AT2) receptors, oxidative stress and fibrotic markers in the aorta of type II diabetic rats | 2015 |
5 | Ms. Vibha Kumari | To study the different animal models for AKI | 2018 |
6 | Ms. Jyotima Mishra | Role PARP inhibitors in fibrosis | 2018 |
7 | Ms. Niharika Shiva | Simultaneous activation of ACE2 and ER stress inhibition in the development of type 1 diabetic cardiomyopathy | 2020 |
8 | Ms. Pooja Dhileepkumar Rao |
Role of ER stress inhibition and ACE2 activation in endothelial dysfunction under hyperglycemic condition
|
2020 |
9 | Mr. Tahib Habshi | Evaluating the renoprotective role of hinokitiol against acute kidney injury under diabetic condition | 2023 |
10 | Mr. Niraj Patil | Exploring the renoprotective potential of bifendate against chronic kidney disease | 2024 |
11 | Ms. Shruti Shreya |
Evaluating the beneficial effects of guaiacol against chronic kidney disease |
2024 |
S.No | Name | Thesis/Project title | Year |
1 | Mr. Monil Thakkar | cGMP for phase I investigational drugs | 2011 |
2 | Ms. Masuma Hasan | Good manufacturing practices for processing of mesenchymal stromal cells | 2011 |
3 | Ms. Anjana Ramnath | Current good manufacturing practices for positron emission tomography drugs | 2011 |
4 | Mr. Karthik Gangavarapu | The Cure: Developing an interactive decision tree builder for breast cancer survival prediction (Co-supervisor) | 2014 |
5 | Ms. Garima | Partial parallelization of de novo genome assembler (Co-supervisor) | 2015 |
6 | Mr. Priyank Raj | Role of epigenetics in the development of liver dysfunction under type II diabetic conditions | 2016 |
7 | Ms. Ananya | Role of hyperglycemia in kidney injury | 2017 |
8 | Mr. Lakshya Sharma | The preclinical and clinical status of klotho: A review of its therapeutic potential in acute and chronic kidney diseases | 2023 |
S.No | Name | Project title | Year |
1 | Ms. Anshima Sharma | Clinical outcomes of SGLT2 inhibitors alone and in combination with existing antidiabetic and cardiovascular therapies: an update | 2021 |
2 | Mr. Uma Mahesh | Epigenetic regulation of ER stress and autophagy in kidney disease | 2021 |
3 | Ms. Anjana S. | Herbal medicine-the future of diabetic nephropathy treatment | 2021 |
4 | Mr. Tahib Habshi | Role of endoplasmic reticulum stress and autophagy in acute kidney injury to chronic kidney disease transition | 2022 |
5 | Ms. Tathambika Sen | Novel promising therapeutic targets for kidney diseases: Emphasis on kidney-specific proteins | 2022 |
6 | Ms. Soumya Sikka | Role of lncRNAs in the regulation of ER stress in AKI/Kidney diseases | 2022 |
7 | Mr. Vinayak Yelgonde | Epigenetic regulation of organelle dynamics in kidney diseases | 2022 |
8 | Ms. Swati Mishra | Immunosuppression in AKI: What to prefer or to avoid | 2023 |
9 | Mr. Mayur Chandanani | Future therapeutics and biomarkers for diabetic kidney disease: A clinical review | 2023 |
10 | Ms. Shruti Shreya | Future therapeutics for type 1 diabetes: A clinical review | 2023 |
11 | Ms. Shubhangi Saxena | Unveiling the therapeutic potential of metabolic reprogramming targeted therapies in kidney diseases | 2023 |
12 | Mr. Hrushikesh Kulkarni |
The crucial nexus of Polo-like kinase 1 (PLK1) in pathogenesis of kidney diseases |
2024 |
This website uses cookies or similar technologies, to enhance your browsing experience.